Skip to content

Spyre Therapeutics

US · SYRE #1646 by market cap Listed 1970
93.47 -4.16 -4.26%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

About Spyre Therapeutics

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Founded
2013
CEO
Dr. Cameron Turtle, D.Phil.
Employees
102
Headquarters
Waltham, Massachusetts, United States of America
Fiscal year end
12-31
Website
spyre.com

Company profile

Exchange
US
Symbol
SYRE
Market-cap rank
#1646
Listing date
1970-01-01
Market cap
8.88B
Float cap
8.65B
Shares out
94.97M
Float shares
92.51M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Spyre Therapeutics discussion 0 comments

Add a comment